447 related articles for article (PubMed ID: 26929609)
1. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
[TBL] [Abstract][Full Text] [Related]
2. Reasons for Not Treating Women with Postmenopausal Osteoporosis with Prescription Medications: Physicians' and Patients' Perspectives.
Weaver JP; Olsson K; Sadasivan R; Modi A; Sen S
J Womens Health (Larchmt); 2017 Dec; 26(12):1302-1311. PubMed ID: 28994642
[TBL] [Abstract][Full Text] [Related]
3. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
Gold DT; Bonnick SL; Amonkar MM; Kamel HK; Agarwal S; Zaidi M
Gend Med; 2008 Dec; 5(4):374-84. PubMed ID: 19108810
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of anti-osteoporosis treatment after hip fracture.
Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
[TBL] [Abstract][Full Text] [Related]
7. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
[TBL] [Abstract][Full Text] [Related]
8. Patient treatment preferences for osteoporosis.
Fraenkel L; Gulanski B; Wittink D
Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
[TBL] [Abstract][Full Text] [Related]
9. Management of osteoporosis in the Middle East and North Africa: a survey of physicians' perceptions and practices.
Beshyah SA; Al-Saleh Y; El-Hajj Fuleihan G
Arch Osteoporos; 2019 Jun; 14(1):60. PubMed ID: 31175470
[TBL] [Abstract][Full Text] [Related]
10. Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study.
Roux C; Baron G; Briot K; Roux B; Cortet B; Thomas T
Osteoporos Int; 2017 Dec; 28(12):3339-3345. PubMed ID: 28852785
[TBL] [Abstract][Full Text] [Related]
11. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.
Watson J; Wise L; Green J
Eur J Clin Pharmacol; 2007 Sep; 63(9):843-9. PubMed ID: 17598097
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
[TBL] [Abstract][Full Text] [Related]
13. Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey.
Fallowfield L; Jenkins V; Coleman R
Breast; 2008 Oct; 17(5):459-63. PubMed ID: 18455921
[TBL] [Abstract][Full Text] [Related]
14. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
[TBL] [Abstract][Full Text] [Related]
16. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
17. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
18. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
Beard MK
Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
[TBL] [Abstract][Full Text] [Related]
20. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
